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ReviewCdc25 Phosphatases and Cancer
of the eukaryotic cell cycle (Figure 1). The Cdk/cyclinsK. Kristja´nsdo´ttir and J. Rudolph*
Departments of Biochemistry and Chemistry are subject to numerous counteracting control mecha-
nisms, including association with inhibitory proteins suchDuke University Medical Center
LSRC Building, Room C125 as p15Ink4b/p16Ink4a or p21Waf1/p27Kip1, activating phosphor-
ylations on Thr160/161 of the T-loop by the Cdk-activat-Durham, North Carolina 27710
ing kinase, and inhibitory phosphorylation on Thr14 and
Tyr15 by the Wee1 and Myt1 kinases [2]. The three hu-
man Cdc25s, Cdc25A, Cdc25B, and Cdc25C, are re-
sponsible for the dephosphorylation of pThr14 andThe Cdc25 phosphatases function as key regulators
of the cell cycle during normal eukaryotic cell division pTyr15 and thereby trigger the final activation of the
Cdk/cyclin complexes. Cdc25B and Cdc25C are regula-and as mediators of the checkpoint response in cells
with DNA damage. The role of Cdc25s in cancer has tors of G2/M through their activity on Cdk2/cyclin A,
Cdk1/cyclinA, and Cdk1/cyclin B (Figure 1). Cdc25A hasbecome increasingly evident in recent years. More
than 20 studies of patient samples from diverse can- a more general role in controlling both the G1/S and
G2/M transitions [3]. Positive and negative feedbackcers show significant overexpression of Cdc25 with
frequent correlation to clinical outcome. Recent screen- activation loops between the Cdk/cyclins and the Cdc25s
ensure abrupt and irreversible transitions during normaling and design efforts have yielded novel classes of
inhibitors that show specificity for the Cdc25s over cell cycle progression.
The Cdc25 phosphatases also play a key role in inte-other phosphatases and cause cell cycle arrest in vivo.
Herein we provide a single source for those interested grating the specific signals of checkpoint control in re-
sponse to damage by ionizing irradiation (IR), ultravioletin the cellular functions of Cdc25 in cell cycle progres-
sion, its role in the progress of cancer and survival of light (UV), replication inhibitors, and DNA damaging
agents at each of the stages of the cell cycle (Figure 1)cancer patients, and recent efforts in the design of
specific inhibitors. [4]. In response to IR, cells undergo rapid G1 arrest as
a result of ubiquitin/proteasome-mediated degradation
of Cdc25A and consequential maintenance of Cdk2/
cyclin E in the phosphorylated and inactive state. This
degradation of Cdc25A is triggered by Chk1 phosphory-
lation of Cdc25A as mediated through the ATM (ataxia-Introduction
According to the World Health Organization (2000), ap- telangiectasia-mutated) pathway. Similarly, the response
to UV irradiation and replication inhibitors also causesproximately 10 million new cases of cancer are diag-
nosed worldwide each year, causing 6%–12% of all hu- Cdc25A degradation, this time through Chk1 phosphor-
ylation and the ATR (ATM- and Rad3-related) pathway.man deaths. Liver, stomach, lung, and breast cancer are
among the cancers with the highest morbidity. Although In the S-phase checkpoint response to IR, Cdc25A inte-
grates the signals from the ATM-Chk2 and ATR-Chk1each type of cancer, even individual cases of cancer,
can arise from diverse causes and can exhibit various pathways to yield a rapid and sustained cell cycle arrest,
again leading to the preservation of Cdk2 in the inactivetraits, common features shared by all cancers are a
disordered cell cycle and irregularities such as dele- state. In the G2/M checkpoint, Cdc25A and Cdc25C
become important downstream effectors of the Chk1tions, overexpression, or mutations in the molecules that
control this cycle. The Cdc25 phosphatases are cell response. Phosphorylation of Cdc25A on Thr507 and
Cdc25C on Ser216 leads to 14-3-3-mediated sequestra-cycle control proteins whose overexpression is fre-
quently associated with a wide variety of cancers. In tion of the phosphatases away from their substrates
and consequential maintenance of Cdk1/cyclin B in thethis review of the Cdc25 phosphatases, we first consider
the role of Cdc25 in cell cycle control and oncogenic phosphorylated and inhibited state. Cdc25B and the
polo-like kinases PLK1 and PLK3 have also been impli-transformation, and then discuss 20 different reports of
Cdc25 overexpression in human cancers. We finish by cated in the G2/M checkpoint response.
reviewing recent progress toward inhibiting the Cdc25
phosphatases using small molecule inhibitors.
Cdc25 Structure and Mechanism
The human Cdc25s are between 423 and 566 amino
acids long. The N-terminal regulatory domains have lowCdc25 and Cell Cycle Control
sequence homology (20%–25% identity) and containThe Cdc25 phosphatases are key for cell cycle control
sites for phosphorylation, sequestration by 14-3-3, ubi-in eukaryotes under normal conditions and in response
quitination, and proline isomerization. Modifications atto DNA damage (reviewed in [1]). The physiological sub-
these sites are involved in both normal cell cycle controlstrates of the Cdc25 phosphatases are the cyclin-
and in response to checkpoint signals. There exist atdependent kinases (Cdk/cyclins), the central regulators
least three splice variants for Cdc25A, five for Cdc25B,
and five for Cdc25C [5]. The question of splice variants
is of specific importance for Cdc25B, as the most active*Correspondence: rudolph@biochem.duke.edu
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Figure 1. Cdc25s Are Involved in a Complex
Web of Cellular Interactions Wherein They
Function to Regulate Cell Cycle Progression
under Normal Cell Growth and in Response
to DNA or Oxidative Damage
of the splice forms (Cdc25B2) is the only variant de- lography. As suggested by the lack of sequence conser-
vation outside of the CX5R motif, the overall fold of thetected in primary fibroblasts, whereas at least three dif-
ferent splice forms are found in immortalized fibroblasts Cdc25s differs from other protein tyrosine phospha-
tases. The active site loop, however, is superimposable[6]. As most studies do not differentiate between the
different splice variants, little is known about the relative on the active sites of other diverse protein tyrosine phos-
phatases (Figure 2). A key feature of the Cdc25s is theirimportance of the different forms. The catalytic domains
are located in the more homologous C termini (60% lack of a deep active site pocket (Figure 3). There exists
no obvious groove for binding protein or small moleculeidentity) and are able to dephosphorylate protein sub-
strates as rapidly as full-length protein [7]. The catalytic substrates, consistent with the lack of activity or speci-
ficity toward peptidic substrates [7]. It is presumed thatdomains contain the CX5R motif common to all protein
tyrosine phosphatases, where C is the catalytic cysteine a remote binding site mediates specific recognition of
protein substrate.and the amide backbones of the five X residues form a
phosphate binding loop along with the arginine R (Figure The mechanism of the Cdc25 phosphatases has many
similarities to the well-established mechanism of the2). Until recently, the catalytic domains were not thought
to undergo covalent modifications. However, in Cdc25A, protein tyrosine phosphatases, in particular the dual-
specificity phosphatases (Figure 4) [14]. The active siteChk1 phosphorylation of Thr507 within the C-terminal
substrate-docking tail is thought to govern 14-3-3 and cysteine exists as a thiolate with a pKa of 5.9 [15, 16]
and forms a transient covalent intermediate consistingcyclin B binding in the control of mitosis [8]. Also, oxida-
tion of the active site cysteine by reactive oxygen spe- of a phospho-cysteine. Para-nitrophenyl phosphate is
a poor substrate (kcat/Km  15 M1s1) and probes thecies may be involved in the checkpoint response to
oxidizing conditions in the cell [9–11]. first half of the reaction, whereas the rate determining
step is breakdown of the phospho-enzyme intermediateThe structures of the catalytic domains of Cdc25A
[12] and Cdc25B [13] have been solved by X-ray crystal- for the better substrate O-methyl fluorescein phosphate
Figure 2. The Active Site Loop of Cdc25B
Overlays with the Active Site Loops of the
Human Vh1-Related Dual-Specificity Phos-
phatase and the Yersinia Protein Tyrosine
Phosphatase, Despite Having Different Over-
all Protein Folds
The amide backbone and the arginine of the
active site loop form hydrogen bonds with
the bound sulfate that mimics phosphate
binding. The beginning of a conserved  helix
that provides a favorable dipole for mainte-
nance of the cysteinyl anion is also shown.
The figure was generated using VMD from
Protein Data Bank ID codes 1qb0, 1vhr, and
1yts, and only the side chains of the active
site cysteine and the arginine are shown for
clarity.
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Cdc25 and Oncogenic Transformation
From their initial discovery in humans, Cdc25s have
been linked to oncogenic transformation [18]. Coexpres-
sion of oncogenic mutants of H-Ras with human Cdc25A
or Cdc25B but not with Cdc25C in normal mouse embryo
fibroblasts led to formation of transformed foci. Cells
from individual foci grew readily in soft agar and induced
tumor formation in nude mice. Expression of Cdc25A
alone in retinoblastoma-deficient but not p53-deficient
fibroblasts also lead to foci formation, growth in soft
agar, and tumor formation in mice.
Subsequent studies in a number of model systems
have since confirmed an oncogenic role for the Cdc25
phosphatases, although overexpression of Cdc25B in
the mammary glands of mice has yielded conflicting
data. In one study, enhanced proliferation of mammary
epithelial cells resulted in the formation of precocious
alveolar hyperplasia [19]. Using a similar overexpression
strategy, another study saw no changes in mammary
cells or elsewhere; however, the mice had an increased
susceptibility to carcinogen-induced mammary tumors
[20]. The oncogenic nature of the Cdc25 phosphatases
has also been found in C. elegans, where a gain-of-
function allele of the cdc-25.1 gene causes excess pro-
liferation of intestinal cells, and its reduction by RNAiFigure 3. The Active Site of Cdc25B Is Adjacent to an Inhibitor Bind-
ing Pocket and the Attachment Site of the C-Terminal Tail leads to reduced proliferation of a variety of cell types
Shown is the active site surface of Cdc25B with key features in [21]. Interestingly, the mitotic cdc25C/ mouse is via-
licorice, such as the active site loop, the residues that surround the ble, develops normally, and does not display any obvi-
inhibitor binding pocket adjacent to the active site (R482, R544, and ous abnormalities [22]. The cdc25B/ mouse is also
T547), and the attachment point of the C-terminal tail, which is not
viable and responds normally to DNA damage, althoughvisible in the crystal structure. The figure was generated using VMD
the females are sterile, as their oocytes are unable tofrom Protein Data Bank ID code 1qb0.
undergo meiosis [23]. In both cases, it is speculated
that the missing Cdc25 function may be complemented
by one of the remaining Cdc25s.(kcat/Km  104 M1s1). The bis-phosphorylated protein
substrate Cdk2/CycA is by far the best substrate for
Cdc25 (kcat/Km  106 M1s1). For the protein substrate, Cdc25 Overexpression
Here, we summarize and comment on the techniquesphospho-threonine is preferentially dephosphorylated,
whereas phospho-tyrosine is preferred in the poorly uti- and results of the Cdc25 overexpression studies [18,
24–42]. Over half of the 15 different cancers studiedlized peptidic substrates (kcat/Km  1  10 M1s1) [7].
The origin of the catalytic acid that protonates the leav- (taken together) showed overexpression of both Cdc25A
and Cdc25B isoforms (Table 1). The remainder showeding group has not been unambiguously established. The
glutamate adjacent to the catalytic cysteine (Glu432 in overexpression of either Cdc25A or Cdc25B, and there
was no significant overexpression of Cdc25C. We thenCdc25A and Glu474 in Cdc25B) has been suggested to
serve this role using small molecule substrates [17] but discuss the mechanism and consequences of Cdc25
overexpression in human cancers.has been ruled out using the protein substrate [15, 16].
There is evidence that the catalytic acid resides on the Experimental Techniques
A total of 20 studies spanning from 1995 to 2004 thatprotein substrate itself, either on an amino acid side
chain or on the phosphate of the phospho-threonine. investigated the overexpression of Cdc25 phospha-
tases in human tumor samples were reviewed (TableThis proposed substrate-assisted catalysis would help
explain the high specificity for, and reactivity with, the 1). Cdc25A, Cdc25B, and Cdc25C overexpression was
specifically addressed in 15, 19, and 10 of these studies,correct protein substrate.
Figure 4. Two-Step Reaction Mechanism of
the Cdc25 Phosphatases with a Covalent
Phospho-Cysteine Intermediate
The identity of the catalytic acid has not been
firmly established.
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respectively. The studies represent 14 types of human are of greatest relevance, but are difficult due to issues
of substrate specificity (only phosphorylated Cdk/cyclincancer and account for a majority of all cancer deaths.
The total number of patients included in these studies complexes should be used), low cellular levels of Cdc25,
and the sensitivity of the phosphatase to mild oxidationwas 1558 (range 20–181, mean 68). The diversity of can-
cers and patient populations make direct comparisons during sample preparation.
Cdc25 Overexpression Resultsbetween studies essentially impossible. On the other
hand, the consistent overexpression of Cdc25 testifies From the initial observation of Cdc25B overexpression in
breast cancer [18] to the more recent and very thoroughto the role of Cdc25 and its value as a marker, prognosti-
cator, and important target for inhibition by small mole- study in [29] and the direct measurement of phospha-
tase activity in patient-derived cell lines [43], there hascules.
In evaluating these Cdc25 overexpression studies, it been a clear and consistent trend associating Cdc25
with breast cancer. These studies also consistentlyis important to consider the experimental techniques
employed. First, it is not expected that levels of mRNA, show that Cdc25 is overexpressed in only a subpopula-
tion (32%–47%). Importantly, the overexpression ofprotein concentration, and protein activity will necessar-
ily correlate. This is particularly true for the Cdc25 phos- Cdc25A or Cdc25B in breast cancer correlates with clini-
cal outcome, as is the case for ovarian [37] and colo-phatases in the context of cancerous cells, as the process
of immortalization perturbs many of the mechanisms of rectal cancer [31]. Cdc25A and Cdc25B are also both
overexpressed in a subpopulation of non-Hodgkin’spost-translational modification known to affect Cdc25
phosphatases (see above). Second, from an experimen- lymphoma [39, 40]. Although correlation with mortality
was not reported, overexpression did correlate stronglytal viewpoint, multiple techniques are valuable toward
verifying results and eliminating bias. Commendably, we with aggressive high-grade lymphomas. Esophageal
[26–28], gastric [34], lung [35], thyroid [38], and head andfound that 14 of the 20 studies utilized multiple ap-
proaches to confirm overexpression of the Cdc25s. neck cancers [33] also show overexpression of Cdc25A
(40%–80%) and Cdc25B (17%–78%).The most common technique employed in the re-
viewed studies was immunohistochemistry (IHC). The Cancers such as hepatocellular carcinoma [24] that
specifically overexpress only Cdc25A appear to be rare.strength of this technique is that it preserves the tissue
architecture and thus allows identification of protein Pancreatic ductal carcinoma [32] and gastric carcino-
mas [34] are the only two types of cancer for whichexpression levels in cancerous cells compared to sur-
rounding tissues, including intracellular localization. exclusive Cdc25B overexpression has been seen. The
Cdc25C phosphatase appears to be a conundrum.Strongly linking Cdc25 overexpression directly with can-
cer, both Cdc25A and Cdc25B staining in these 22 stud- Given its prominent role in promoting the G2/M transition
[1] and its role in S phase in human cells [44], it wasies is found exclusively in cancerous tissues, with the
exception of [32], where Cdc25B is also seen in the expected to play an important role in cancer progres-
sion. However, consistently from the first study in breastsurrounding dedifferentiating cells and some fibro-
blasts. Cdc25A is found to be nuclear, except in [37], cancer [18], significant overexpression of Cdc25C has
not been associated with any of the nine different can-where it is mostly cytoplasmic, and in [27] and [38],
where it is mixed. In contrast, Cdc25B is mostly cyto- cers that have been tested.
In general, although both Cdc25A and Cdc25B areplasmic, with the exception of [17], where it is nuclear,
and [26] and [32], where it is both. The problems with overexpressed in a majority of the cancers studied, a
correlation between Cdc25A and Cdc25B overexpres-IHC arise from the variable percentage cut-offs used in
determining overexpression, ranging from 10% [26, 34] sion has not been observed [27, 33], except in the study
of non-Hodgkin’s lymphoma [40]. In that study, 64% ofto 75% [31, 37], with a more typical value of 50%. Also,
there exist differences in antibody dilutions and sources the patients with high levels of Cdc25A also overex-
pressed Cdc25B. Higher levels of both were seen in(Santa Cruz and Cell Signaling were the most common
suppliers), as well as tissue preparation and preser- 50% of aggressive tumors and in less than 4% of indo-
lent tumors. Thus, although either Cdc25A or Cdc25Bvation.
The second most common technique employed is is sufficient to drive cell cycle progression in cancerous
cells, the two can collaborate in more aggressive can-reverse transcription polymerase chain reaction (RT-
PCR). Given the low levels of mRNA for the Cdc25 phos- cers. It should be cautioned, however, that overex-
pression of Cdc25B in many of these studies may bephatases, the increased sensitivity of RT-PCR over
Northern blotting is essential to their detection (note the underestimated, and correlations between Cdc25A and
Cdc25B may have been overlooked due to the nondis-direct comparison in [30, 40]). Also, if properly designed,
RT-PCR also allows for the detection of alternative crimination between splice variants of Cdc25B [30]. In
the future, it will be necessary to examine the levelssplice variants, of which many have been found to exist,
as noted above. Importantly, a high level of a constant of the different splice variants and their actual cellular
activity in greater detail.splice variant can obscure changes in the low level of
a different splice variant [40]. On the other hand, mRNA Mechanism of Overexpression
The mechanism of Cdc25 overexpression is not clearlevels do not necessarily reflect protein levels for the
Cdc25s and may not reflect phosphatase activity, as despite numerous attempts to shed light on this impor-
tant question. It is evident from studies in colorectalthe splice variant Cdc25C2 lacks the catalytic domain.
Other techniques used include Western blotting (WB), [30], gastric [34], non-Hodgkin’s [39], nonsmall cell lung
[35], and ovarian cancers [37] that gene amplification isanti-sense riboprobes, Northern blots (NB), phospha-
tase assays, and cDNA arrays. Of course, activity assays not the cause of Cdc25 overexpression. The role of the
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proto-oncogene and transcription factor c-Myc has
been controversial. It was originally shown that both
cdc25A and cdc25B were targets of c-Myc, as they both
contain functional binding sites for Myc/Max [45]. Since
then, many of the overexpression studies have looked
for a correlation between c-Myc and Cdc25 expression.
A positive correlation has been detected in non-Hodg-
kin’s lymphoma, although other mechanisms of Cdc25B
upregulation must exist, as the correlation was not 100%
[39]. A positive correlation has also been reported for
neuroblastoma [41] and for nonsmall cell lung in one
study [36] yet not another [35]. There is also no correla-
tion between Cdc25A and c-Myc in melanoma from pa-
tient-derived cell lines [46]. Given the presence of Myc
target sites in both cdc25A and cdc25B, a correlation
between phosphatase expression and Myc should also
reveal a correlation between the two phosphatases. As
noted above, this is rarely seen, although it may be
underdetected due to the splice variant problem. An
alternative mechanism of overexpression has been sug-
gested wherein post-translational modification leads to
an enhanced stability of Cdc25A [43]. Thus, the mecha-
nism of Cdc25 overexpression, in most cases, is an
important open problem, and its further elucidation may
reveal novel anticancer targets.
Figure 5. Representative Examples of a Number of the More Well-Role of Cdc25 Overexpression in Cancer
Studied or Recently Identified Inhibitors of the Cdc25 PhosphatasesAs Cdc25 phosphatases promote cell cycle progression
and are overexpressed in numerous rapidly dividing
cancer cells, one might expect a correlation between
of the more well-studied compounds include Vitamin K3Cdc25 overexpression and the rate of proliferation. In
and its derivatives, the dysidiolides, sulfiricins, quino-fact, no correlation has been seen in the majority of
linediones, and naphthoquinone (Figure 5). Vitamin K3cases examined [28–31, 35, 38]. The only case with a
(menadione) and its thioalkyl derivatives (e.g., com-reported correlation was non-Hodgkin’s lymphoma [39],
pound 5) have IC-50s of 1–15 M and covalently modifywhere 74% of cells with high levels of Cdc25B were
Cdc25 phosphatases by arylation. In cell-based assays,found in S phase, compared to only 20% in those cells
these compounds lead to G1/S and G2/M arrest, consis-with low levels of Cdc25B. Thus, the role of Cdc25 over-
tent with inhibition of Cdc25s, although their potencyexpression is more complicated than that of a simple
may be diminished through reduction by quinone reduc-driver of cell proliferation. It is quite likely that Cdc25
tase [48]. The natural product dysidiolide and many sub-overexpression in tumors is required to circumvent
sequent derivatives have been probed as potentialmany of the checkpoints that would otherwise hinder
Cdc25 inhibitors (IC-50s of 0.8–16 M), although thecell proliferation. In support of this view, a lack of re-
potency of the parent compound has been questioned.sponse to ionizing radiation was seen in breast cancer
Sulfiricin, another natural product, has been investi-cell lines overexpressing Cdc25A [43], similar to the re-
gated by extensive preparation and testing of deriva-sults for overexpression of Cdc25B in esophageal can-
tives (IC-50s of 2–9 M), yet it shows no selectivity forcers [28]. Absence of a proper checkpoint response
Cdc25 over other tyrosine phosphatases.causes premature entry into the G2/M transition, leading
A number of novel inhibitors have been discoveredto inappropriate distribution of chromosomes and aneu-
through a collaborative effort at the University of Pitt-ploidy. The lack of proper checkpoint control contrib-
burgh. SC-9 is a competitive inhibitor of the Cdc25sutes to the malignant nature of the tumors, as noted in
(IC-50 of 15 M), blocks cells in G1 and G2/M, leads tomany of the overexpression studies.
increased phosphorylation of multiple Cdk/cyclin com-
plexes, and is cytotoxic to breast carcinoma cells. The
hydrophobicity of the side chain and the aromatic moietyTherapeutic Potentials
The therapeutic strategy prescribed by the strong link on the oxazole ring appear to be the critical components
for Cdc25 inhibition. The quinolinediones, originallybetween Cdc25 and cancer has been to pursue the
development of specific Cdc25 inhibitors. Although the identified from the NCI Diversity Set, have been exten-
sively characterized. Compound NSC663284 has an IC-shallow active site and the high reactivity of the catalytic
cysteine of the Cdc25s suggests that this may be a 50 of 200 nM and a 20-fold specificity toward Cdc25B
versus the Vh1-related dual specificity phosphatasedifficult goal, a number of recent publications demon-
strate that progress is being made. The detailed chemis- (VHR). NSC663284, like compound 5, also covalently
modifies the active site of Cdc25, surprisingly, throughtry of many small molecule inhibitors of Cdc25 has re-
cently been well reviewed [5, 47]. The inhibitors are one of the serines, not the cysteine [49]. In cell-based
assays, NSC663284 causes G2/M arrest, and, unlike thederived from many diverse chemical classes, and some
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Vitamin K derivatives, its potency is not affected by beyond antiproliferation assays and evaluate the effect
of compounds on synchronized cells, as done, for exam-cellular quinone reductase concentrations [48]. The
para-naphthoquinone NSC95397 is the most potent ple, with the tsFT210 cell line [49] or synchronized HeLa
cells [52]. Even better, a direct effect on the intracellularCdc25 inhibitor to date (IC-50s of 22–125 nM). Again,
this compound blocks the G2/M transition and shows substrates of Cdc25 can be shown by increased inhibi-
tory phosphorylation on the Cdk/cyclins (see for exam-growth inhibition against human carcinoma cell lines.
New inhibitor classes not previously reviewed include ple [49, 52, 57]). However, as many different pathways
feed into cell cycle control (Figure 1), non-Cdc25-spe-the indolyl-dihydroxy-quinones [50], the suramins [51],
BN82002 [52], and the cyclopentaquinoline and naptho- cific cellular insults are also expected to cause G1/S or
G2/M arrest. For example, cellular stress mediated byfurandione inhibitors [53] (Figure 5). From the indolyl-
dihydroxy-quinones, compound 8L is a competitive in- the p38 and Jnk kinases determines whether a cell prog-
resses through the cell cycle, enters senescence, orhibitor, with a Ki of 0.43M against Cdc25B and appears
to bind in the pocket adjacent to the active site (Figure undergoes apoptotic cell death, and thus inhibitors of
dual-specificity phosphatases involved in MAP kinase3). Inhibition by these compounds requires the C-ter-
minal tail, shown previously to be involved in protein control (e.g., MKP-3) can also yield cell cycle arrest
phenotypes. Specifically, NSC663284, described as asubstrate recognition [54]. Compound 8L shows activity
when challenged with the protein substrate, and treat- Cdc25 inhibitor, was recently rediscovered in a screen
for inhibition of ERK dephosphorylation [58]. Also, thement of HEK293 cells with 50 M of compound 8L
causes rapid apoptosis by an unknown mechanism. The promiscuity of the thioalkyl derivatives of Vitamin K is
evident in the pull-down assays with biotinylated com-suramin derivatives NF201, NF336, and NF339 have IC-
50s from 2–4 M and show 20- to 50-fold specificity pound 5, which show a large number of other potential
targets that remain to be characterized [56].over a series of other human phosphatases but have
not been tested in cell-based assays. BN82002 has an Based on Cdc25s effects on checkpoints in tumors,
not the rate of cell proliferation, a better measure ofIC-50 of 5.4 M and has been shown to inhibit cell cycle
progression in synchronized HeLa cells. Impressively Cdc25 inhibition in the context of human might be to test
for compound-dependent restoration of the checkpointdemonstrating that Cdc25 is the likely intracellular tar-
get, BN82002 is able to reverse the premature chromo- response in cell lines overexpressing Cdc25 [43]. Alter-
natively, reversal of the mitotic effect caused by tran-some condensation caused by transient overexpression
of Cdc25B in HeLa cells. The newest and most interest- sient overexpression of Cdc25B in HeLa cells appears
to be a novel cell-based assay with specificity for Cdc25ing compounds discovered in Lazo’s laboratory are the
napthofurandiones (5169131) [53]. These compounds [52]. These alternative assays are difficult to implement
in large-scale screening but are important in follow-upare competitive versus small molecule substrates, and
docking studies suggest that they also bind in the pocket assays of interesting lead molecules, given the sensitiv-
ity of cell cycle control to multiple signaling pathways.adjacent to the active site (Figure 3). In cell-based
assays, 5169131 leads to both G1/S and G2/M arrest Recently, a novel yeast-based screening method has
been described that may be useful for discovering noveland causes a concomitant increase in the inhibitory
phosphorylation of Cdk1. inhibitors, though not addressing any of the complica-
tions of human cells [59].There exists some discrepancy in the reported poten-
cies of a number of Cdc25 inhibitors in vitro, which most A completely alternative approach to Cdc25 overex-
pression, as suggested by some clinical correlationslikely arises from two causes. First, Cdc25 is particularly
susceptible to nonspecific inhibitors that exhibit enzyme- [28], is to aggressively treat Cdc25-overexpressing sub-
populations with radiation therapy. Normal radiation-concentration-dependent IC-50s (unpublished observa-
tions; see also [55]). Thus, the presence or absence of induced cell cycle arrest is abrogated in these tumors,
and therefore radiation treatment results in apoptosisdetergents, the clog p value of the compound, and the
absolute concentration of enzyme can greatly alter the of the cancerous cells. From this point of view, an activa-
tor of Cdc25 activity could be a useful radiation- ormeasured potency. Second, the highly reactive cysteine
at the active site of the Cdc25s is particularly suscepti- chemo-sensitizer in tumors that do not overexpress
Cdc25. The daunting task of developing activators ofble to covalent modification by many classes of com-
dual-specificity phosphatases has not yet been pur-pounds, and therefore inhibition constants will vary
sued. On the other hand, an increase in Cdc25 activitydepending on assay conditions. For example, the Vita-
can also be attained by inhibition of a negative regulatormin K derivatives [56], the quinolinediones [49], and
of Cdc25 (Figure 1). To this end, inhibitors of Chk1 haveBN82002 [52] all modify residues within the active site
shown good promise. For example, UCN-01 and theloop, although, surprisingly, not always the active site
indolocarbazole SB-218078 are nanomolar inhibitors ofcysteine.
Chk1 and enhance the cytotoxicity of DNA damage byThe real difficulty in Cdc25 inhibitor studies lies in
abrogating the G2/M checkpoint response [60, 61]. Clini-demonstrating specific targeting of Cdc25 in cell-based
cal trials combining UCN-01 with various chemo-sensi-experiments. The presence of three potentially comple-
tizers, such as prednisone, irinotecan, fluorouracil, andmenting isoforms has precluded the clear delineation
cis-platin, are underway.of a Cdc25 inhibition phenotype in higher eukaryotes
using mouse knockout studies, siRNA, or antisense
DNA. Based on the known biology described above, it Future Directions
Although much has been learned, the future of researchis expected that a pan-Cdc25 inhibitor would block cell
cycle progression. Thus, good cell-based assays will go in the Cdc25 field promises many exciting advances.
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